Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial

NCT03694197 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT03694197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03694197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 4
Overall status
Terminated
Start date
September 28, 2018
Completion date
April 8, 2020
Enrollment
1,389 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

heterozygous familial hypercholesterolemia, non-familial hypercholesterolemia